The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Molecular Mechanisms of Antisense Oligonucleotides
Open accessAbstract
In 1987, when I became interested in the notion of antisense technology, I returned to my roots in RNA biochemistry and began work to understand how oligonucleotides behave in biological systems. Since 1989, my research has focused primarily on this topic, although I have been involved in most areas of research in antisense technology. I believe that the art of excellent science is to frame large important questions that are perhaps not immediately answerable with existing knowledge and methods, and then conceive a long-term (multiyear) research strategy that begins by answering the most pressing answerable questions on the path to the long-term goals. Then, a step-by-step research pathway that will address the strategic questions posed must be implemented, adjusting the plan as new things are learned. This is the approach we have taken at Ionis. Obviously, to create antisense technology, we have had to address a wide array of strategic questions, for example, the medicinal chemistry of oligonucleotides, manufacturing and analytical methods, pharmacokinetics and toxicology, as well as questions about the molecular pharmacology of antisense oligonucleotides (ASOs). Each of these endeavors has consumed nearly three decades of scientific effort, is still very much a work-in-progress, and has resulted in hundreds of publications. As a recipient of the Lifetime Achievement Award 2016 granted by the Oligonucleotide Therapeutic Society, in this note, my goal is to summarize the contributions of my group to the efforts to understand the molecular mechanisms of ASOs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Cisplatin : current status and new developments
Prestayko, A. W., Crooke, S. T., Carter, S. K., & Laboratories, B. (1980) · Cited by 747
Self-citationCellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Self-citationEfficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Self-citationTherapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.32.040192.001553 · Cited by 446
Self-citationProgress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Self-citationYu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., & Corey, D. R. (2012) · Cell · doi:10.1016/j.cell.2012.08.002 · Cited by 278
Self-citationSalomon, W. E., Jolly, S. M., Moore, M. J., Zamore, P. D., & Serebrov, V. (2015) · Cell · doi:10.1016/j.cell.2015.06.029 · Cited by 270
Antisense Drug Technology: Principles: Strategies, and Applications
(2021) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 268
An integer linear programming approach for finding deregulated subgraphs in regulatory networks
Backes, C., Rurainski, A., Klau, G. W., Müller, O., Stöckel, D., Gerasch, A., Küntzer, J., Maisel, D., Ludwig, N., Hein, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1227 · Cited by 259
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications
Szymkowski, D. E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02123-7 · Cited by 218
Burel, S. A., Hart, C. E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.-H., Younis, H., Sabripour, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1210 · Cited by 216
Self-citationLiang, X.-H., Shen, W., Sun, H., Migawa, M. T., Vickers, T. A., & Crooke, S. T. (2016) · Nature Biotechnology · doi:10.1038/nbt.3589 · Cited by 212
Self-citationBleomycin: current Status and New Developments
Bush, H. (1979) · British Journal of Cancer · doi:10.1038/bjc.1979.184 · Cited by 196
Liang, X.-H., Sun, H., Shen, W., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv143 · Cited by 182
Self-citationProperties of Cloned and Expressed Human RNase H1
Wu, H., Lima, W. F., & Crooke, S. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28270 · Cited by 159
Self-citationCellular uptake and intracellular trafficking of oligonucleotides
Juliano, R. L., & Carver, K. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.005 · Cited by 140
Crooke, S. T. (2004) · Current Molecular Medicine · doi:10.2174/1566524043360375 · Cited by 139
Self-citationJuliano, R. L., Ming, X., Carver, K. A., & Laing, B. M. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0463 · Cited by 135
Binding and Cleavage Specificities of Human Argonaute2
Lima, W. F., Wu, H., Nichols, J. G., Sun, H., Murray, H. M., & Crooke, S. T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.010835 · Cited by 127
Self-citation2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
Shen, W., Liang, X., Sun, H., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv298 · Cited by 111
Self-citationBleomycin : current status and new developments
Carter, S. K., Crooke, S. T., UMEZAWA, H., Program, N. C. C., & Laboratories, B. (1978) · Academic Press eBooks · Cited by 110
Self-citationAntisense Research and Application
Crooke, S. T. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6 · Cited by 109
Self-citationLima, W. F., Murray, H. M., Damle, S. S., Hart, C. E., Hung, G., Hoyos, C. L. D., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw350 · Cited by 107
Self-citationPhosphorothioate oligonucleotides can displaceNEAT1RNA and form nuclear paraspeckle-like structures
Shen, W., Liang, X., & Crooke, S. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku579 · Cited by 103
Self-citationReduced levels of Ago2 expression result in increased siRNA competition in mammalian cells
Vickers, T. A., Lima, W. F., Nichols, J. G., & Crooke, S. T. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm663 · Cited by 95
Self-citationLiang, X., Shen, W., Sun, H., Prakash, T. P., & Crooke, S. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku484 · Cited by 94
Self-citationLima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Siwkowski, A. M., & Crooke, S. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025015 · Cited by 89
Self-citationVickers, T. A., & Crooke, S. T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv920 · Cited by 87
Self-citationLima, W. F., Nichols, J. G., Wu, H., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405035200 · Cited by 83
Self-citationLiang, X., Shen, W., Sun, H., Kinberger, G. A., Prakash, T. P., Nichols, J. G., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw144 · Cited by 79
Self-citationAnnexin A2 facilitates endocytic trafficking of antisense oligonucleotides
Wang, S., Sun, H., Tanowitz, M., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw595 · Cited by 77
Self-citationDevelopment of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions
Vickers, T. A., & Crooke, S. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161930 · Cited by 74
Self-citationLima, W. F., Hoyos, C. L. D., Liang, X., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw065 · Cited by 73
Self-citationVickers, T. A., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108625 · Cited by 72
Self-citationHuman RNase H1 Is Associated with Protein P32 and Is Involved in Mitochondrial Pre-rRNA Processing
Wu, H., Sun, H., Liang, X., Lima, W. F., & Crooke, S. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071006 · Cited by 58
Self-citationMolecular Cloning and Expression of cDNA for Human RNase H
Wu, H., Lima, W. F., & Crooke, S. T. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.53 · Cited by 56
Self-citationLiang, X., Hart, C. E., & Crooke, S. T. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.01.011 · Cited by 50
Self-citationMechanisms of Antisense Drug Action, an Introduction
Vickers, T., Wu, H., Crooke, S., & Lima, W. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-7 · Cited by 49
Self-citationDefining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
Lima, W. F., Vickers, T. A., Nichols, J. G., Li, C., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101752 · Cited by 48
Self-citationHodges, D., & Crooke, S. T. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10549-x · Cited by 48
Self-citationLima, W. F., Murray, H., Nichols, J. G., Wu, H., Sun, H., Prakash, T. P., Berdeja, A., Gaus, H. J., & Crooke, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803748200 · Cited by 45
Self-citationLima, W. F., Wu, H., Nichols, J. G., Prakash, T. P., Ravikumar, V. T., & Crooke, S. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306543200 · Cited by 41
Self-citationLima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Vasquez, G., Swayze, E. E., & Crooke, S. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025429 · Cited by 39
Self-citationLima, W. F., Wu, H., & Crooke, S. T. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)41168-2 · Cited by 34
Self-citationLima, W. F., Wu, H., & Crooke, S. T. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-8 · Cited by 27
Self-citationU1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP
Vickers, T. A., Sabripour, M., & Crooke, S. T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr150 · Cited by 23
Self-citationHuman RNase H1 Activity Is Regulated by a Unique Redox Switch Formed between Adjacent Cysteines
Lima, W. F., Wu, H., Nichols, J. G., Manalili, S. M., Drader, J. J., Hofstadler, S. A., & Crooke, S. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211279200 · Cited by 21
Self-citationVickers, T. A., Freier, S. M., Bui, H., Watt, A. T., & Crooke, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110615 · Cited by 16
Self-citationVickers, T. A., & Crooke, S. T. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks239 · Cited by 9
Self-citation
Cited by
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Metadata
- Authors
- Crooke, S. T.
- Venue
- Nucleic Acid Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-04
- Volume
- 27
- Issue
- 2
- Pages
- 70-77
- ISSN
- 2159-3337 (ISSN-L)
- 2159-3345
- OpenAlex
- W2576942864
- Cited by
- 396
- References
- 52
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.